Psoriasis Comorbidities at Hospital Calderón Guardia

NCT07448337 | Not Yet Recruiting

• 1 other identifier: CEC HCG 03-2026
• Study Type: observational
• Target: 350
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this observational study is to characterize the epidemiologic, clinical, severity, and therapeutic features of patients with psoriasis treated in Costa Rica between 2024 and 2025. The main questions it aims to answer are: What are the demographic and clinical characteristics and severity profiles of psoriasis patients? What treatments are used in routine clinical practice, and how are they associated with disease severity and outcomes? Patients with psoriasis receiving dermatologic care during the study period will be included. Data will be obtained retrospectively from electronic medical records and clinical registries without intervention or modification of treatment.

Conditions

Psoriasis; Psoriasis Arthritis; Psoriasis (PsO); Psoriasis Patients

Keywords

Comorbidities; Costa Rica; Psoriasis; Real-world data; Disease severity; Epidemiology

Outcome Measures

Primary Outcomes (3)

• Prevalence of Metabolic Comorbidities in Patients With Psoriasis

  Proportion (%) of patients with documented diagnosis of obesity (BMI ≥30 kg/m²), diabetes mellitus (prior diagnosis or HbA1c ≥6.5%), hypertension (prior diagnosis or BP ≥140/90 mmHg), dyslipidemia (prior diagnosis or abnormal lipid profile), and metabolic syndrome.

  2024-2025

• Prevalence of Atherosclerotic Cardiovascular Disease

  Proportion (%) of patients with documented history of coronary artery disease, myocardial infarction, angina/revascularization, ischemic stroke, or peripheral arterial disease.

  2024-2025

• Prevalence of Psoriatic Arthritis

  Proportion (%) of patients with rheumatologist-confirmed diagnosis of psoriatic arthritis, including characterization of predominant clinical domain (peripheral arthritis, axial involvement, enthesitis, dactylitis).

  2024-2025

Secondary Outcomes (4)

• Psoriasis Severity

  2024-2025

• Psoriasis Severity

  2024-2025

• Association Between Psoriasis Severity and Comorbidities

  2024-2025

• Inflammatory and Metabolic Biomarkers

  2024-2025

Eligibility Criteria

• Age: 12 Years+
• Gender Eligibility Details: All
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The study population comprises adolescents and adults (≥12 years) with a confirmed diagnosis of psoriasis documented in the Electronic Health Record (EHR-EDUS) of Hospital Calderón Guardia who were evaluated in outpatient dermatology or rheumatology clinics between 2024 and 2025. Eligible patients received systemic therapy and/or phototherapy for psoriasis and had sufficient clinical information to assess disease severity, metabolic comorbidities, atherosclerotic cardiovascular disease, and psoriatic arthritis. This hospital-based cohort reflects real-world patients with moderate-to-severe psoriasis managed in specialized care within the Costa Rican public health system during the study period.

You may qualify if:

• Patients evaluated in outpatient clinics during the period 2024-2025.
• Patients receiving systemic therapy and/or phototherapy.
• Patients aged 12 years or older, of any sex.
• Availability of sufficient clinical information to assess psoriasis severity, metabolic comorbidities, atherosclerotic cardiovascular disease, and psoriatic arthritis.
• At least one dermatologic or rheumatologic evaluation recorded in the Electronic Health Record (EHR-EDUS) during the study period.
• Confirmed diagnosis of psoriasis documented in the Electronic Health Record (EHR-EDUS) of Hospital Calderón Guardia.

You may not qualify if:

• Clinical records insufficient to evaluate psoriasis severity, comorbidities, or therapeutic profile.
• Patients managed exclusively with topical therapies.
• Duplicate or inconsistent records, preventing accurate patient classification.
• Cutaneous conditions not compatible with psoriasis.

Sponsors & Collaborators

• Caja Costarricense de Seguro Social: lead

Study Sites (1)

Caja Costarricense del Seguro Social

San José, Provincia de San José, 40901, Costa Rica

Location

MeSH Terms

Conditions

Psoriasis

Condition Hierarchy (Ancestors)

Skin Diseases, Papulosquamous; Skin Diseases; Skin and Connective Tissue Diseases

Central Study Contacts

Daniel E Barquero-Orias, Dermatologist

CONTACT

+506 83411026; debarque@ccss.sa.cr

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER GOV
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Sub-Investigator

Study Record Dates

• First Submitted: February 26, 2026
• First Posted: March 4, 2026
• Study Start: May 1, 2026
• Primary Completion (Estimated): May 1, 2027
• Study Completion (Estimated): May 1, 2027
• Last Updated: April 8, 2026

Record last verified: 2026-04

Data Sharing

• IPD Sharing: Will not share

Locations

CO (1)